67 related articles for article (PubMed ID: 16024645)
1. Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice.
He L; Feng H; Raymond A; Kreeger M; Zeng Y; Graner M; Whitesell L; Katsanis E
Cancer Immunol Immunother; 2001 Mar; 50(1):31-40. PubMed ID: 11315508
[TBL] [Abstract][Full Text] [Related]
2. In vitro differentiated plasmacytoid dendritic cells as a tool to induce anti-leukemia activity of natural killer cells.
Díaz-Rodríguez Y; Cordeiro P; Belounis A; Herblot S; Duval M
Cancer Immunol Immunother; 2017 Oct; 66(10):1307-1320. PubMed ID: 28555259
[TBL] [Abstract][Full Text] [Related]
3. Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells.
Carlsten M; Järås M
Front Immunol; 2019; 10():2357. PubMed ID: 31681270
[TBL] [Abstract][Full Text] [Related]
4. In vitro analysis of microRNA-26a in chronic lymphocytic leukemia cells.
Li J; Sun CK
Int J Mol Med; 2018 Dec; 42(6):3364-3370. PubMed ID: 30320374
[TBL] [Abstract][Full Text] [Related]
5. Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission.
Hughes A; Yong ASM
Front Immunol; 2017; 8():469. PubMed ID: 28484463
[TBL] [Abstract][Full Text] [Related]
6. Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay.
Perrotti D; Silvestri G; Stramucci L; Yu J; Trotta R
Curr Drug Targets; 2017; 18(4):377-388. PubMed ID: 27307150
[TBL] [Abstract][Full Text] [Related]
7. Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia.
Baragaño Raneros A; Martín-Palanco V; Fernandez AF; Rodriguez RM; Fraga MF; Lopez-Larrea C; Suarez-Alvarez B
Genes Immun; 2015; 16(1):71-82. PubMed ID: 25393931
[TBL] [Abstract][Full Text] [Related]
8. Secretory pathways generating immunosuppressive NKG2D ligands: New targets for therapeutic intervention.
Baragaño Raneros A; Suarez-Álvarez B; López-Larrea C
Oncoimmunology; 2014; 3():e28497. PubMed ID: 25050215
[TBL] [Abstract][Full Text] [Related]
9. Molecular Bases for the Regulation of NKG2D Ligands in Cancer.
Huergo-Zapico L; Acebes-Huerta A; López-Soto A; Villa-Álvarez M; Gonzalez-Rodriguez AP; Gonzalez S
Front Immunol; 2014; 5():106. PubMed ID: 24711808
[TBL] [Abstract][Full Text] [Related]
10. The role of natural killer cells in chronic myeloid leukemia.
Danier AC; de Melo RP; Napimoga MH; Laguna-Abreu MT
Rev Bras Hematol Hemoter; 2011; 33(3):216-20. PubMed ID: 23049299
[TBL] [Abstract][Full Text] [Related]
11. NK cells sense tumors, course of disease and treatments: Consequences for NK-based therapies.
Fregni G; Perier A; Avril MF; Caignard A
Oncoimmunology; 2012 Jan; 1(1):38-47. PubMed ID: 22720210
[TBL] [Abstract][Full Text] [Related]
12. Long circulating lectin conjugated paclitaxel loaded magnetic nanoparticles: a new theranostic avenue for leukemia therapy.
Singh A; Dilnawaz F; Sahoo SK
PLoS One; 2011; 6(11):e26803. PubMed ID: 22110595
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of current cancer immunotherapy: hemato-oncology.
Hourigan CS; Levitsky HI
Cancer J; 2011; 17(5):309-24. PubMed ID: 21952281
[TBL] [Abstract][Full Text] [Related]
14. NKG2D ligand expression in human colorectal cancer reveals associations with prognosis and evidence for immunoediting.
McGilvray RW; Eagle RA; Watson NF; Al-Attar A; Ball G; Jafferji I; Trowsdale J; Durrant LG
Clin Cancer Res; 2009 Nov; 15(22):6993-7002. PubMed ID: 19861434
[TBL] [Abstract][Full Text] [Related]
15. The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia.
Chakraverty R; Sykes M
Blood; 2007 Jul; 110(1):9-17. PubMed ID: 17327406
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic use of Aldara in chronic myeloid leukemia.
Marleau AM; Lipton JH; Riordan NH; Ichim TE
J Transl Med; 2007 Jan; 5():4. PubMed ID: 17254347
[TBL] [Abstract][Full Text] [Related]
17. BCR/ABL promotes dendritic cell-mediated natural killer cell activation.
Terme M; Borg C; Guilhot F; Masurier C; Flament C; Wagner EF; Caillat-Zucman S; Bernheim A; Turhan AG; Caignard A; Zitvogel L
Cancer Res; 2005 Jul; 65(14):6409-17. PubMed ID: 16024645
[TBL] [Abstract][Full Text] [Related]
18. Altered IFNgamma signaling and preserved susceptibility to activated natural killer cell-mediated lysis of BCR/ABL targets.
Cebo C; Voutsadakis IA; Da Rocha S; Bourhis JH; Jalil A; Azzarone B; Turhan AG; Chelbi-Alix M; Chouaib S; Caignard A
Cancer Res; 2005 Apr; 65(7):2914-20. PubMed ID: 15805294
[TBL] [Abstract][Full Text] [Related]
19. Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cells.
Smit WM; Rijnbeek M; van Bergen CA; de Paus RA; Vervenne HA; van de Keur M; Willemze R; Falkenburg JH
Hum Immunol; 1997 Apr; 53(2):216-23. PubMed ID: 9129981
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
